Financial Enhancement Group LLC Takes Position in Inari Medical, Inc. (NASDAQ:NARI)

Financial Enhancement Group LLC acquired a new stake in Inari Medical, Inc. (NASDAQ:NARI) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 28,002 shares of the company’s stock, valued at approximately $1,155,000.

Several other large investors have also recently made changes to their positions in the business. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Inari Medical in the first quarter worth about $30,000. GAMMA Investing LLC lifted its stake in Inari Medical by 164.7% in the second quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after purchasing an additional 438 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after purchasing an additional 435 shares during the period. Covestor Ltd increased its position in Inari Medical by 30.2% in the first quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after buying an additional 376 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its stake in shares of Inari Medical by 39.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after buying an additional 522 shares during the period. 90.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on NARI shares. Leerink Partnrs raised Inari Medical to a “hold” rating in a report on Tuesday, September 3rd. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. Stifel Nicolaus initiated coverage on shares of Inari Medical in a report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price objective for the company. Piper Sandler boosted their target price on shares of Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a report on Tuesday, October 29th. Finally, Truist Financial raised their price target on Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a report on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $58.89.

Insider Buying and Selling at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the completion of the transaction, the director now owns 643,296 shares of the company’s stock, valued at approximately $29,482,255.68. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director William Hoffman sold 40,000 shares of Inari Medical stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the completion of the sale, the director now directly owns 643,296 shares of the company’s stock, valued at approximately $29,482,255.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Mitch C. Hill sold 3,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now owns 179,600 shares of the company’s stock, valued at $8,105,348. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 131,000 shares of company stock valued at $6,161,340 in the last 90 days. Corporate insiders own 10.60% of the company’s stock.

Inari Medical Stock Performance

Shares of NARI stock opened at $53.27 on Thursday. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.13. The business’s fifty day moving average is $44.10 and its 200 day moving average is $46.35. The company has a market capitalization of $3.12 billion, a PE ratio of -39.46 and a beta of 0.96.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.